Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 8, 2007, Pages 899-906

  Diago, M ^a,ah   Olveira, A ^b   Sola R ^c   Romero Gomez M ^d   Moreno Otero, R ^e   Perez R ^f   Salmeron J ^g   Enriquez J ^h   Planas, R ⁱ   Gavilan J C ^j   Del Olmo, J ^k   Uribarrena, R ^l   Sillero, C ^m   Benitez A ⁿ   Sanchez Galdon S ^o   Dalmau, B ^p   Erana L ^q   Montoro, M ^r   Portu, J ^q   Garijo, J M ^s   Barniol, R ^t   Dominguez A ^u   Rota, R ^v   Olcoz, J L ^w   Anton M ^x   Pamplona, X ^y   Casanovas, T ^z   Jimenez E ^aa   Huarte, M ^ab   Diaz F ^ac   Sanchez Ruano J ^ad   Orive, M ^ae   Munoz Sanchez M ^af   Roset, M ^ag   more..

^a H General   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c H del Mar   (Spain)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^h H Sant Pau   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j H Virgen de la Victoria   (Spain)

^k Servicio de Dermatología   (Spain)

^l H Miguel Servet   (Spain)

^m Orthopedic Surgery and Traumatology Service   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^o H Punta Europa   (Spain)

^p Hospital Parc Tauli   (Spain)

^q HOSPITAL TXAGORRITXU   (Spain)

^r San Jorge General Hospital   (Spain)

^s Department of Internal Medicine   (Spain)

^t H Vic   (Spain)

^u Servicio de Medicina Interna   (Spain)

^v H de Viladecans   (Spain)

^w Virgen Blanca   (Spain)

^x H Virgen Blanca ^*  (Spain)

^y H Santa Caterina   (Spain)

^z H Bellvitge   (Spain)

^aa H Insular   (Spain)

^ab Hospital Materno Infantil Virgen Del Camino   (Spain)

^ac HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^ad HOSPITAL VIRGEN DE LA SALUD   (Spain)

^ae HOSPITAL DE BASURTO   (Spain)

^af Roche Farma   (Spain)

^ag Health Outcomes Research Europe   (Spain)

^ah HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; IRRITABILITY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; PANCREATITIS; PARANOIA; PATIENT COMPLIANCE; POLYARTHRITIS; PRIORITY JOURNAL; PRURITUS; SEIZURE; SIDE EFFECT; SUICIDAL IDEATION; THROMBOCYTE COUNT; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 34047137162     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03270.x     Document Type: Article

References (11)

1. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225-30.
2. National Institutes of Health (NIH) Consensus Statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46.
3. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64; quiz 14-7.
4. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
7. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-33.
8. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
9. Lee SS, Bain VG, Peltekian K, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006; 23: 397-408.
10. Jacobson I, Brown R, Freilich B, et al. Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R study, A US community based trial. Hepatology 2005; 42 (Suppl. 1): 749A.
11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.